CytomX Therapeutics (NASDAQ: CTMX) details Q3 2025 results and update

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. filed a current report to let investors know it has released unaudited financial results for the third quarter and first nine months of 2025. The company did this through a press release dated November 6, 2025, which also includes a broader business update.

The press release is furnished as Exhibit 99.1 to the report, meaning it is provided for information but is not treated as formally filed for liability purposes under certain securities laws. CytomX’s common stock continues to trade on the Nasdaq Global Select Market under the symbol CTMX.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001501989false00015019892025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

CytomX Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37587	27-3521219
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
151 Oyster Point Blvd Suite 400
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 515-3185

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		CTMX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results for the three and nine months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished as part of this report.

Exhibit No.		Description
99.1		Press release titled "CytomX Therapeutics Announces Third Quarter of 2025 Financial Results and Provides Business Update" issued by CytomX Therapeutics, Inc. on November 6, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CYTOMX THERAPEUTICS, INC.
Date:	November 6, 2025	By:	/s/ Christopher W. Ogden
			Christopher W. Ogden Chief Financial Officer

FAQ

What did CytomX Therapeutics (CTMX) disclose in this 8-K filing?

CytomX Therapeutics furnished a press release reporting its unaudited financial results for the three and nine months ended September 30, 2025, and provided a business update.

Which period do the CytomX Therapeutics (CTMX) results in this filing cover?

The results cover the three and nine months ended September 30, 2025, as described in the furnished press release.

How did CytomX Therapeutics (CTMX) provide its Q3 2025 financial results?

The company issued a press release on November 6, 2025, reporting its unaudited financial results and business update, which is attached as Exhibit 99.1.

Is the CytomX Therapeutics (CTMX) press release considered filed with the SEC?

No. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to certain liabilities under the Securities Exchange Act and Securities Act.

What exhibits are included with this CytomX Therapeutics (CTMX) 8-K?

The report includes Exhibit 99.1, a press release titled "CytomX Therapeutics Announces Third Quarter of 2025 Financial Results and Provides Business Update," and Exhibit 104, the cover page interactive data file.

Who signed this CytomX Therapeutics (CTMX) 8-K report?

The report was signed on behalf of CytomX Therapeutics, Inc. by Christopher W. Ogden, the company’s Chief Financial Officer, on November 6, 2025.